CTX130, an anti-CD70 CAR-T therapy, is under development for T-cell lymphoma (NCT04502446) and renal cell carcinoma (RCC, NCT04438083), employing electroporation for ex vivo gene editing. The gene discussed is CD70; the disease is renal cell carcinoma.